CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 87 filers reported holding CYTOSORBENTS CORP in Q4 2018. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $15,304 | -48.2% | 4,263 | -51.4% | 0.00% | – |
Q1 2023 | $29,531 | +105367.9% | 8,763 | +48583.3% | 0.00% | – |
Q4 2022 | $28 | -98.6% | 18 | -98.9% | 0.00% | – |
Q3 2022 | $2,000 | -50.0% | 1,654 | 0.0% | 0.00% | – |
Q2 2022 | $4,000 | -69.2% | 1,654 | 0.0% | 0.00% | – |
Q3 2021 | $13,000 | -74.5% | 1,654 | -75.1% | 0.00% | – |
Q1 2020 | $51,000 | +2450.0% | 6,648 | +1595.9% | 0.00% | – |
Q3 2019 | $2,000 | +100.0% | 392 | +326.1% | 0.00% | – |
Q2 2019 | $1,000 | 0.0% | 92 | 0.0% | 0.00% | – |
Q1 2019 | $1,000 | -97.4% | 92 | -98.0% | 0.00% | – |
Q4 2018 | $38,000 | -40.6% | 4,664 | -6.6% | 0.00% | -100.0% |
Q3 2018 | $64,000 | -45.3% | 4,991 | -51.2% | 0.00% | 0.0% |
Q2 2018 | $117,000 | +5750.0% | 10,221 | +3924.0% | 0.00% | – |
Q3 2017 | $2,000 | -89.5% | 254 | -94.3% | 0.00% | – |
Q2 2017 | $19,000 | -34.5% | 4,454 | -29.9% | 0.00% | – |
Q1 2017 | $29,000 | +314.3% | 6,354 | +369.3% | 0.00% | – |
Q4 2016 | $7,000 | -12.5% | 1,354 | +8.0% | 0.00% | – |
Q3 2016 | $8,000 | – | 1,254 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 450,000 | $846,000 | 0.90% |
Skylands Capital, LLC | 2,944,670 | $5,535,980 | 0.84% |
Sargent Investment Group, LLC | 1,257,048 | $2,363,250 | 0.57% |
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 197,940 | $372,127 | 0.52% |
Avenir Corp | 2,717,397 | $5,108,706 | 0.48% |
Granahan Investment Management | 1,552,393 | $2,918,499 | 0.10% |
Seelaus Asset Management LLC | 20,450 | $38,446 | 0.04% |
HighMark Wealth Management LLC | 10,000 | $18,800 | 0.02% |
Key Client Fiduciary Advisors, LLC | 13,000 | $24,440 | 0.02% |
Eudaimonia Partners, LLC | 23,500 | $44,180 | 0.01% |